Literature DB >> 17653509

Immediate effect of fluvastatin on lipid levels in acute coronary syndrome.

Petr Ostadal1, David Alan, Jiri Vejvoda, Jana Cepova, Jiri Kukacka, Peter Blasko, Lucia Martinkovicova, Jan Vojacek.   

Abstract

It is widely assumed that acute benefit of statin therapy is mediated especially by non-lipid effects. The immediate influence of statins on lipid levels in patients with acute coronary syndrome (ACS) is, however, not clear. A total of 64 consecutive patients with ACS were randomized at admission to fluvastatin 80 mg (Group 1, N = 32) or standard therapy without statin (Group 2, N = 32). The levels of total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), high-density-lipoprotein cholesterol (HDL-C), and triglycerides (TG) were examined at admission and after 24 h. Baseline characteristics were comparable in both groups. In Group 1, fluvastatin significantly decreased the levels of TC by 14.5%, LDL-C by 17.2%, and HDL-C by 10.0% (P < 0.001); TG were not influenced. In Group 2 only marginal reductions in TC (by 4.1%, P = 0.03) and HDL-C (by 7.5%, P < 0.01) were detected; the levels of LDL-C and TG were not changed. As compared with Group 2, in Group 1 the final levels of TC (P = 0.02) and LDL-C (P = 0.01) were significantly lower. Fluvastatin therapy, when started at admission in patients with ACS, significantly reduces TC and LDL-C already after 24 h. We suggest that the lipid-lowering effect of statins in the therapy of ACS is probably as prompt as non-lipid effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17653509     DOI: 10.1007/s11010-007-9549-8

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  28 in total

1.  Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials.

Authors:  Matthias Briel; Gregory G Schwartz; Peter L Thompson; James A de Lemos; Michael A Blazing; Gerrit-Anne van Es; Meral Kayikçioglu; Hans-Richard Arntz; Frank R den Hartog; Nic J G M Veeger; Furio Colivicchi; Jocelyn Dupuis; Shinya Okazaki; R Scott Wright; Heiner C Bucher; Alain J Nordmann
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

Review 2.  Statins and the acute coronary syndrome: 'the early bird catches the worm'.

Authors:  P Nair; A Roguin
Journal:  Int J Clin Pract       Date:  2006-06       Impact factor: 2.503

3.  The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level.

Authors:  Dimitris Tousoulis; Charalambos Antoniades; Vasiliki Katsi; Erini Bosinakou; Maria Kotsopoulou; Costas Tsioufis; Christodoulos Stefanadis
Journal:  Int J Cardiol       Date:  2005-07-06       Impact factor: 4.164

4.  Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women.

Authors:  S Marchesi; G Lupattelli; D Siepi; G Schillaci; G Vaudo; A R Roscini; H Sinzinger; E Mannarino
Journal:  J Cardiovasc Pharmacol       Date:  2000-11       Impact factor: 3.105

5.  The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol.

Authors:  Mehmet Kanadaşi; Murat Cayli; Mustafa Demirtaş; Tamer Inal; Mesut Demir; Mevlut Koç; Mahir Avkaroğullari; Yurdaer Dönmez; Ayhan Usal; Cumhur C Alhan; Mustafa San
Journal:  Heart Vessels       Date:  2006-09-29       Impact factor: 2.037

6.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

7.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2004-08-30       Impact factor: 56.272

8.  Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway.

Authors:  Robert M Bell; Derek M Yellon
Journal:  J Am Coll Cardiol       Date:  2003-02-05       Impact factor: 24.094

9.  Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia.

Authors:  Jian-Jun Li; Ming-Zhe Chen; Xin Chen; Chun-Hong Fang
Journal:  Clin Cardiol       Date:  2003-10       Impact factor: 2.882

10.  Statins in the first-line therapy of acute coronary syndrome - similar to aspirin?

Authors:  Petr Ostadal; David Alan; Jiri Vejvoda
Journal:  Exp Clin Cardiol       Date:  2005
View more
  5 in total

1.  Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial).

Authors:  Petr Ostadal; David Alan; Jiri Vejvoda; Jiri Kukacka; Milan Macek; Petr Hajek; Martin Mates; Milan Kvapil; Jiri Kettner; Martin Wiendl; Ondrej Aschermann; Josef Slaby; Frantisek Holm; Peter Telekes; David Horak; Peter Blasko; David Zemanek; Josef Veselka; Jana Cepova
Journal:  Trials       Date:  2010-05-25       Impact factor: 2.279

2.  Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome.

Authors:  Dagmar Vondrakova; Petr Ostadal; Andreas Kruger
Journal:  Lipids Health Dis       Date:  2010-07-14       Impact factor: 3.876

3.  Statins as first-line therapy for acute coronary syndrome?

Authors:  Petr Ostadal
Journal:  Exp Clin Cardiol       Date:  2012

4.  Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers.

Authors:  Petr Ostadal; Dagmar Vondrakova; Andreas Kruger; Marek Janotka; Hana Psotova; Miroslav Prucha
Journal:  Lipids Health Dis       Date:  2012-11-10       Impact factor: 3.876

5.  The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects.

Authors:  H R Xu; W L Chen; N N Chu; X N Li; J R Zhu
Journal:  J Biomed Biotechnol       Date:  2012-07-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.